小儿高级别胶质瘤中PD-L1与miR-155的相互作用

PD-L1/miR-155 Interplay in Pediatric High-Grade Glioma.

作者信息

Litak Jakub, Grajkowska Wiesława, Bogucki Jacek, Kowalczyk Paweł, Petniak Alicja, Podkowiński Arkadiusz, Szumiło Justyna, Kocki Janusz, Roliński Jacek, Rahnama-Hezavah Mansur, Roszkowski Marcin, Grochowski Cezary

机构信息

Department of Immunology, Medical University of Lublin, 20-093 Lublin, Poland.

Department of Pathology, The Children's Memorial Health Institute, 04-730 Warsaw, Poland.

出版信息

Brain Sci. 2022 Feb 28;12(3):324. doi: 10.3390/brainsci12030324.

DOI:10.3390/brainsci12030324

PMID:35326280

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8946275/

Abstract

High-grade pediatric glioma (p-HGG-WHO 2021, formerly GBM-WHO 2016), as a common, aggressive, and highly lethal primary brain malignancy in adults, accounts for only 3-15% of primary brain tumors in pediatric patients. After leukemia, brain malignancies are the second most common in the pediatric population and first in incidences concerning solid tumors. This study was designed on the basis of 14 pediatric patients hospitalized at Children's Memorial Health Institute in Warsaw, Poland, due to p-HGG treatment. All the patients had a histopathological diagnosis performed by an experienced neuropathologist according to WHO guidelines (WHO 2016 Grade IV Glioblastoma). A significant correlation was found between the miR-155 concentration and the level of PD-L1 expression in p-HGG tumor tissue. Very few reports have indicated PD-L1 expression in pediatric patients.

摘要

高级别小儿胶质瘤（2021年世界卫生组织分类为p-HGG，之前2016年世界卫生组织分类为胶质母细胞瘤），作为成人中常见、侵袭性强且致死率高的原发性脑恶性肿瘤，在小儿患者的原发性脑肿瘤中仅占3%-15%。仅次于白血病，脑恶性肿瘤是小儿群体中第二常见的疾病，在实体瘤发病率中位列第一。本研究基于14名因p-HGG治疗而在波兰华沙儿童纪念健康研究所住院的小儿患者展开。所有患者均由经验丰富的神经病理学家根据世界卫生组织指南（2016年世界卫生组织IV级胶质母细胞瘤）进行组织病理学诊断。在p-HGG肿瘤组织中，发现miR-155浓度与PD-L1表达水平之间存在显著相关性。关于小儿患者中PD-L1表达的报道极少。